Materials / Specialty ChemicalsUpdated 2026-05-10 22:07 UTC

BGLC stock hub

BioNexus Gene Lab Corp. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

BGLCis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

BGLC

In the news

Latest news · BGLC

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 10.4P50 15.8P75 24

Trailing P/En/a

P25 15.7P50 22.1P75 35.3

ROE-35.2

P25 -20.7P50 0.8P75 14.1

ROIC-69.2

P25 -9.3P50 3.2P75 11.3

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All BGLC market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

195

Groups with data

Currency

USD

Showing 195 of 195 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001737523
Company name	BioNexus Gene Lab Corp.
Country	Malaysia
Country code	US
Cusip	090628306
Employees	19
Employees Change	-13%
Employees Change Percent	-40.63
Enterprise value	$1.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Specialty Chemicals
Isin	US0906283066
Last refreshed	2026-05-10
Market cap	$5M
Market cap category	Nano-Cap
Price	$2.06
Price currency	USD
Rev Per Employee	390,784.79x
Sector	Materials
Sic	8071
Symbol	BGLC
Website	https://www.bionexusgenelab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-59.94%
EV/Sales	0.16x
FCF yield	-37.66%
P/B ratio	0.58x
P/S ratio	0.67x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-41.74%
EBITDA Margin	-40.23%
Gross margin	14.62%
Gross Profit	$1.1M
Gross Profit Growth	-15.84%
Gross Profit Growth3 Y	-4.83%
Gross Profit Growth5 Y	-8.8%
Net Income	$-3M
Net Income Growth Years	0%
Pretax Margin	-40.2%
Profit Margin	-40.2%
Profit Per Employee	$-157,085
ROA	-19.68
Roa5y	-8.84
ROCE	-35.49
ROE	-35.24
Roe5y	-15.9
ROIC	-69.2
Roic5y	-35.15

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-22.86%
Cagr3y	-59.27%
Cagr5y	-60.79%
EPS Growth Years	0
FCF Growth Q	346.18%
OCF Growth Q	338.44%
Revenue Growth	-21.93x
Revenue Growth Q	-80.83x
Revenue Growth Years	0x
Revenue Growth3 Y	-12.09x
Revenue Growth5 Y	-8.2x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.75
Assets	$9.3M
Cash	$4M
Current Assets	$5.4M
Current Liabilities	$520,957
Debt	$225,525
Debt Equity	$0.03
Equity	$8.6M
Interest Coverage	-158.6
Liabilities	$637,856
Long Term Assets	$3.8M
Long Term Liabilities	$116,899
Net Cash	$3.8M
Net Cash By Market Cap	$76.6
Net Cash Growth	-8.09%
Net Debt Equity	$-0.44
Tangible Book Value	$8.6M
Tangible Book Value Per Share	$3.56
WACC	15.87

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.46
Inventory Turnover	6.14
Net Working Capital	$996,702
Quick ratio	9
Working Capital	$4.9M
Working Capital Turnover	$1.43

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.2%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-22.85%
200-day SMA	3.98
3Y total return	-93.25%
50-day SMA	2.3
50-day SMA vs 200-day SMA	50under200
5Y total return	-99.07%
All Time High	414
All Time High Change	-99.5%
All Time High Date	2020-10-21
All Time Low	1.92
All Time Low Change	7.29%
All Time Low Date	2026-02-10
ATR	0.09
Beta	2.19
Beta1y	1.11
Beta2y	0.89
Ch YTD	-47.85
High	2.15
High52	15.6
High52 Date	2025-07-01
High52ch	-86.79%
Low	2.05
Low52	1.92
Low52 Date	2026-02-10
Low52ch	7.29%
Ma50ch	-10.43%
Price vs 200-day SMA	-48.22%
RSI	40.66
RSI Monthly	33.42
RSI Weekly	32.44
Sharpe ratio	0.62x
Sortino ratio	2.41
Total Return	-4.2%
Tr YTD	-47.85
Tr1m	-10.47%
Tr1w	-0.9%
Tr3m	-2.37%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$-3.1M
Operating margin	-41.74

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1,753,478%
Float Percent	72.54%
Net Borrowing	32,305
Shares Insiders	27.46%
Shares Institutions	2.08%
Shares Out	2,417,314
Shares Qo Q	13.38%
Shares Yo Y	4.2%
Short Float	0.57%
Short Ratio	2.18
Short Shares	0.41

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-2.7M
Average Volume	3,429.6x
Bv Per Share	3.56
CAPEX	$-36,971
Ch1m	-10.47
Ch1w	-0.91
Ch1y	-22.85
Ch3m	-2.37
Ch3y	-93.25
Ch5y	-99.07
Ch6m	-59.53
Change	-0.96%
Change From Open	-4.19
Close	2.08
Days Gap	3.37
Depreciation Amortization	111,873
Dollar Volume	5,693.8
Earnings Date	2026-05-22
Earnings Time	amc
EBIT	$-3.1M
EBITDA	$-3M
EPS	$-1.61
F Score	3
FCF	$-1.9M
FCF EV Yield	-160.91x
FCF Per Share	$-0.78
Financing CF	298,841
Fiscal Year End	December
Founded	2,017
Investing CF	944,751
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-04-14
Last Report Date	2025-12-31
Last Split Date	2025-04-07
Last Split Type	Reverse
Last10k Filing Date	2026-04-14
Ma150	3.48
Ma150ch	-40.75%
Ma20	2.14
Ma20ch	-3.87%
Net CF	-400,583
Next Earnings Date	2026-05-22
Open	2.15
Optionable	No
Position In Range	10
Post Close	2.06
Postmarket Change Percent	-0.49
Postmarket Price	$2.05
Ppne	1,776,506
Price Date	2026-05-08
Ptbv Ratio	0.58
Relative Volume	0.81x
Revenue	7,424,911x
SBC By Revenue	10.7x
Share Based Comp	794,770
Tr6m	-59.53%
Volume	2,764
Z Score	6.65

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does BGLC pay a dividend?

Capital-return profile for this ticker.

Performance

BGLC stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns BGLC?

Insider, institutional, and short-interest positioning.

Institutional ownership

+2.1%

Float: +72.5% of shares outstanding

Insider ownership

+27.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

BGLC momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

40.7

Neutral momentum band

Price vs 200-day MA

-48.2%

50/200-day relationship not available

Beta (5Y)

2.19

More volatile than the market

Sharpe ratio

0.62

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

BGLC vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
LIN	Linde plc	228B	32.7x	6.6x	12.2%	+4.5%	+11.2%	Vender
NEM	Newmont Corporation	124.4B	15.1x	5.0x	26.2%	+16.2%	+118.6%	Compra fuerte

Questions

About BGLC

Hub-level FAQ points readers to the deeper analysis pages.

What is the current BGLC stock rating?

BioNexus Gene Lab Corp. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full BGLC analysis?

The full report lives at /stocks/BGLC/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for BGLC?

The latest report frames BGLC around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the BGLC page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.